Roche Holding Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik im dritten Quartal mit Umsatzwachstum von +7% zu konstanten Wechselkursen (CER) und +8% in CHF fort; Konzernverkäufe steigen in den ersten neun Monaten 2026 um +6% (CER) […]

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA

Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

Roche Generalversammlung 2026

Assemblée générale annuelle 2026 de Roche

MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche